LLY

742.34

+2.24%↑

UNH

524.47

+2.96%↑

JNJ

148.01

+0.7%↑

ABBV

172.39

+0.6%↑

NVO

80.97

+2.85%↑

LLY

742.34

+2.24%↑

UNH

524.47

+2.96%↑

JNJ

148.01

+0.7%↑

ABBV

172.39

+0.6%↑

NVO

80.97

+2.85%↑

LLY

742.34

+2.24%↑

UNH

524.47

+2.96%↑

JNJ

148.01

+0.7%↑

ABBV

172.39

+0.6%↑

NVO

80.97

+2.85%↑

LLY

742.34

+2.24%↑

UNH

524.47

+2.96%↑

JNJ

148.01

+0.7%↑

ABBV

172.39

+0.6%↑

NVO

80.97

+2.85%↑

LLY

742.34

+2.24%↑

UNH

524.47

+2.96%↑

JNJ

148.01

+0.7%↑

ABBV

172.39

+0.6%↑

NVO

80.97

+2.85%↑

Search

AstraZeneca PLC ADR

Cerrado

67.93 1.97

Resumen

Variación precio

24h

Actual

Mínimo

66.62

Máximo

68.37

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+33.15 upside

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

AstraZeneca PLC ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

24 dic 2024, 15:24 UTC

Adquisiciones, fusiones, absorciones

Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million

12 nov 2024, 19:55 UTC

Ganancias

AstraZeneca Expands U.S. Investment Plan -- 3rd Update

12 nov 2024, 11:02 UTC

Ganancias

AstraZeneca Raises Outlook, Plans U.S. Investment -- Update

12 nov 2024, 07:37 UTC

Ganancias

AstraZeneca Raises Outlook on Earnings, Sales Beat

20 ene 2025, 08:02 UTC

Charlas de Mercado

AstraZeneca Trial Results In Focus Amid China Sales Concerns -- Market Talk

18 nov 2024, 10:33 UTC

Charlas de Mercado

Pharmaceutical Sector Outlook for 2025 Looks Rocky -- Market Talk

15 nov 2024, 13:08 UTC

Principales Noticias

Trump's RFK Pick Weighs on Vaccine Makers -- WSJ

15 nov 2024, 10:29 UTC

Acciones populares

Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ

12 nov 2024, 15:30 UTC

Principales Noticias

AstraZeneca Expands U.S. Investment Plan -- 2nd Update

12 nov 2024, 13:39 UTC

Charlas de Mercado

AstraZeneca's Results Make $80B Revenue Target Look Achievable -- Market Talk

12 nov 2024, 10:49 UTC

Charlas de Mercado
Ganancias

AstraZeneca Seen With Positive Momentum at Pivotal Period -- Market Talk

12 nov 2024, 09:52 UTC

Charlas de Mercado

AstraZeneca's New Guidance Could Imply Consensus Upgrades -- Market Talk

12 nov 2024, 07:02 UTC

Ganancias

AstraZeneca Had Seen 2024 Core EPS Growth by Mid Teens Percentage Range

12 nov 2024, 07:02 UTC

Ganancias

AstraZeneca Sees 2024 Core EPS Growth In High Teens Percentage Range

12 nov 2024, 07:02 UTC

Ganancias

AstraZeneca Had Seen 2024 Total Revenue Growth In Mid Teens Percentage Range

12 nov 2024, 07:02 UTC

Ganancias

AstraZeneca Sees 2024 Total Revenue Growth In High Teens Percentage Range

12 nov 2024, 07:02 UTC

Ganancias

AstraZeneca Raises 2024 View

12 nov 2024, 07:01 UTC

Ganancias

Analysts Saw AstraZeneca 3Q Sales at $13.1B

12 nov 2024, 07:01 UTC

Ganancias

Analysts Saw AstraZeneca 3Q Core EPS at $2.04

12 nov 2024, 07:00 UTC

Ganancias

AstraZeneca PLC 3Q EPS 91c

12 nov 2024, 07:00 UTC

Ganancias

AstraZeneca PLC 3Q Net Pft $1.43B

12 nov 2024, 07:00 UTC

Ganancias

AstraZeneca PLC 3Q Oper Pft $2.11B

7 nov 2024, 08:03 UTC

Principales Noticias

China Has Detained a Senior AstraZeneca Executive -- Update

6 nov 2024, 18:55 UTC

Principales Noticias

China Has Detained Senior AstraZeneca Executive -- WSJ

1 nov 2024, 03:00 UTC

Principales Noticias

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

31 oct 2024, 19:48 UTC

Principales Noticias

AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- Update

31 oct 2024, 14:43 UTC

Principales Noticias

AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- WSJ

12 sept 2024, 17:01 UTC

Principales Noticias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 sept 2024, 11:00 UTC

Principales Noticias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

10 sept 2024, 13:08 UTC

Charlas de Mercado

AstraZeneca's Lung Cancer Drug Candidate Disappoints, Lowering Probability of FDA Approval -- Market Talk

Comparación entre iguales

Cambio de precio

AstraZeneca PLC ADR Esperado

Precio Objetivo

By TipRanks

33.15% repunte

Estimación a 12 meses

Media 88.68 USD  33.15%

Máximo 91.7 USD

Mínimo 87 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

65.64 / 66.61Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

$